|
|
|
|
|||||
|
|
|
By Karen Roman
VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation.
“Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio,” said Christoph Erkel, Ph.D., VERAXA’s Vice President Research and Development. “Initiating cell line development with ATUM is an important next step for our lead BiTAC-TCE program following the encouraging preclinical data we presented at AACR.”
Contact:
Click HERE to follow us on LinkedIn
The post VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone appeared first on ExecEdge.
| Jul-13 | |
| Jul-13 | |
| Jul-10 | |
| Jul-09 | |
| Jul-06 | |
| Jul-06 | |
| Jul-06 | |
| Jul-02 | |
| Jul-02 | |
| Jul-02 | |
| Jul-01 | |
| Jun-25 | |
| Jun-24 | |
| Jun-24 | |
| Jun-24 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite